Browsing by Author "Guven Aslan"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    The Effect of Postoperative Early Mobilization on the Healing Process\rand Quality of Life Following Radical Cystectomy and Ileal Conduit:\rA Randomized Prospective Controlled Trial
    (2022) Talha MÜEZZİNOĞLU; Hakan BAYDUR; Ozgur Cakmak; Sevgi VERMİŞLİ; Guven Aslan
    Objective: This study aimed to evaluate the effect of postoperative early mobilization in patients who underwent radical cystectomy (RC) and ileal\rconduit in terms of the healing process and quality of life (QoL).\rMaterials and Methods: This multicenter prospective randomized controlled study included 40 patients who were randomly divided into two\rgroups. The intervention group was mobilized within the first 16 h postoperatively following the mobilization procedure, which was determined\raccording to the literature. Data were collected using the case report form, hospital anxiety and depression scale, and 36-Item Short Form Survey\r(SF-36) QoL scale.\rResults: Postoperative hospitalization, narcotic analgesic administration duration, first oral food intake, flatus, defecation, and nasogastric tube\rtermination time were shorter in the intervention group. Additionally, blood glucose and pulse values were higher in the control group after\rmobilization. SF-36 physical function, physical role difficulty, and general perception of health subscales were higher in the intervention group at\rthe postoperative first and third months (p<0.05).\rConclusion: Early mobilization positively contributed to the healing process and improved the QoL in patients who underwent RC and ileal conduit\rsurgery.
  • No Thumbnail Available
    Item
    Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report
    (2023) Levent Türkeri; Oguzcan Erbatu; Bülent Akdoğan; TALHA MÜEZZINOGLU; Tevfik Sinan Sozen; Sümer Baltacı; Evren SÜER; Guven Aslan; Volkan Izol; Oktay Üçer; Suleyman Ataus; Ilker Tinay
    Objective: This report examined the approaches to low-risk patients using the data from the Urologic Cancer Database - Prostate, Urooncology Association. Materials and Methods: In this study, there were 920 patients with low-risk prostate cancer according to the current guidelines of the European Urology Association. Patient data were obtained from the Urological Cancer Database - Prostate, the Turkish Urooncology Association (UroCaD-P) from records of the years 1995-2021. Ethics committee approval was obtained for this study to publish in the form of a database report. Results: Our study was conducted with 920 patients with low-risk prostate cancer. Therefore, at the time of diagnosis, all patients in the study were ISUP 1, had a prostate specific antigen (PSA) level lower than 10 ng/mL, and clinically T1-T2a. Surgical treatment was used in 750 (81.5%) of the patients. At the time patients were retrieved from the database for the study, 140 patients (15.2%) were in the active surveillance (AS) process. Thirty patients (3.2%) in the study received their local treatment as radiotherapy (RT). The mean age value at cancer detection in the study was 61.9. The mean ages of the patients who were under AS and who underwent radical prostatectomy (RP) were 61.3 and 61.7 years, respectively. In the RT group, the mean age was 66.7 years. The mean PSA value of the whole group was 5.81 ng/mL. While it was 5.94 in AS patients, it was calculated as 5.89 in patients who underwent radical surgery. The mean PSA value of the RT group was 5.40. The pathological upgrade was detected in 225 patients (30%) after surgery. Surgical margin positivity was in 160 of the patients (21.3%) who underwent surgery. In addition, 100 patients (13.3%) had extracapsular disease. The seminal vesicle invasion was detected in 25 patients (3.3%) after surgery. Conclusion: We predict that the incidence of low-risk prostate cancer will increase over time due to the aging of the population, the use of PSA, advances in imaging modalities, and increasing biopsy success rates. Therefore, the importance of the existence of multicentric databases containing this patient group is undeniable. More studies are needed with these databases, including both patient demographics and treatment outcomes. Hopefully, this database report will be an important step in this direction.
  • No Thumbnail Available
    Item
    Can We Predict Recurrence of pT1-2 Renal Cell Carcinoma?
    (2024) Oktay Üçer; Talha MÜEZZİNOĞLU; Guven Aslan; Evren SÜER; Sümer BALTACI; Volkan İZOL; Ender Ozden; Bülent AKDOĞAN; SERTAC YAZICI; ender cem bulut; Nebil Akdogan; Sinan SÖZEN
    Objective: Some prognostic models have been described for localized and metastatic renal cell carcinoma (RCC). The European Association of Urology guidelines on RCC recommend using these models. However, there is no model for T1 and T2. The study evaluated the risk factors for recurrence in T1 and T2 RCC. Materials and Methods: Data of 4823 renal tumor patients from the Renal Tumor Database of the Association of Urooncology in Turkey were evaluated. Of 4823 patients, 1845 RCC patients with pathological T1 or T2 were included in this study. The patients were divided into two groups according to the recurrence status. Anatomical, histological, and clinical prognostic factors were statistically compared between the groups. Afterwards, multivariate analysis was performed for the variables that were found to be statistically significant. Results: The mean follow-up time was 30 (4-180) months. Of 1845 RCC patients, 117 (6.3%) had recurrence. Univariate analysis revealed statistically significant differences between age, preoperative hemoglobin, albumin, neutrophil, alkaline phosphates, platelet and calcium values, histological subtype, Fuhrman grade, surgical technique (radical or partial), and pathological stage in the groups. However, in multivariate analysis, only pathological stage was found to be a risk factor for recurrence (2.17 95%, 1.25-3.77). Conclusions: The results of our study show that it is difficult to design a prognostic model for the recurrence of pT1 and pT2 RCC. We suggest that patients with a higher tumor diameter should be followed up more frequently.